

2027 Abstract Submission Process

INSTRUCTIONS:

Submitted abstracts should be original research studies that highlight novel, unpublished work. Please include the following sections: Background, Aims, Methods, Results, and Conclusion (400 maximum word count).

DEADLINES:

Abstract Submission Deadline: **Monday, June 15th (Midnight EDT)**

Abstract Notification: **Monday, August 3rd**

ABSTRACT CATEGORIES:

Supportive Care and Survivorship:

Abstracts in this category should be focused on the physical, emotional, social, and economic challenges faced by GCT patients during and after the completion of treatment, including management of short and long-term treatment side effects. Additionally, this category encompasses research centered around understanding genetic susceptibility and/or predisposition to certain side effects.

Care for GCT in Low- and Middle-Income Countries:

Abstracts in this category should be centered around clinical research, studies, or interventions conducted in environments where there is a notable lack of access to essential resources, which can be due to healthcare system constraints, infrastructure constraints, and/or level of socio-economic development.

Epidemiology and Health Outcomes:

Abstracts in this category explore the incidence, prevalence, and social determinants of GCT, with a focus on understanding how genetic, environmental, and lifestyle factors interact to influence the risk of GCT. This includes identification and exploration into biomarkers that can reveal insights into disease mechanisms, susceptibility, and progression. Additionally, this category includes abstracts that focus on health outcomes, which may involve the effectiveness of interventions, treatments, or preventive measures.

Clinical Trial: Methodology, Results and Secondary Analyses:

Abstracts in this category include primary findings from clinical trials, including key outcomes and statistical significance. It also encompasses secondary analyses that explore additional hypotheses or provide deeper insights into the data. Secondary analyses might involve examining subgroups, assessing the impact of different variables, or exploring alternative endpoints.

Novel Therapeutics and Diagnostics:

Abstracts in this category showcase novel GCT therapeutic strategies or interventions that represent significant advancements beyond traditional treatments. This could include new drugs, biologics, medical devices, surgical techniques, or other therapeutic modalities.

Molecular and Cellular Biology of GCT:

Abstracts in this category include ongoing research or discovery in the areas of GCT gene expression and regulation, genomics, molecular pathways and mechanisms of disease, developmental and translational biology, and AI/machine learning.